Sanofi which recognizes a "failure" in the development of its anti-Covid vaccine, the pressure which decreases on French hospitals, the turnover of Pfizer boosted by its vaccine ...
Le Figaro
takes stock this Tuesday, May 3 on the latest information related to the Covid-19 pandemic.
Read the fileCovid-19: the coronavirus pandemic in figures and infographics
22,849 patients hospitalized in France
The pressure on hospitals continues to decrease in France, according to data from Public Health France.
In total, French hospitals had 22,849 patients affected by Covid on Tuesday, against 23,211 the day before.
Among them, 1463 were admitted to critical care, including 142 admissions in the last 24 hours.
The macabre count of the pandemic continues: 123 deaths are to be deplored in hospitals in the last 24 hours.
Read alsoCovid long: three quarters of hospitalized patients struggle to recover
Anti-Covid vaccine: Sanofi recognizes a “failure”
The French pharmaceutical giant Sanofi admitted on Tuesday that it had suffered a
“failure”
in the development of an anti-Covid vaccine, a niche in which it is clearly behind competitors like the American Pfizer.
"It is, it must be recognized, a failure (...) compared to the speed that was needed"
, admitted the president of the group, Serge Weinberg.
This is the first time that the group has expressed itself in such a clear-cut manner on the subject, these declarations having been made before its shareholders at a general meeting.
Several of them took the opportunity to question the leaders of the group about its poor performance in the development of an anti-Covid vaccine.
At present, Sanofi has managed to develop only one vaccine against the disease, and it is still under review in the United States and the European Union.
In parallel with this vaccine, said to be recombinant protein and developed in collaboration with the British GSK, Sanofi also tried to develop an anti-Covid vaccine with messenger RNA, but it had to give it up.
These failures, which however hardly affected the group's performance on the stock market because its activity is far from being limited to this niche, contrast with the performance of competitors such as the American Pfizer which launched on the market more than a an a messenger RNA vaccine.
Read alsoSanofi's anti-Covid vaccine finally ready
Pfizer's sales jump in the first quarter, boosted by the anti-Covid vaccine
The American pharmaceutical group Pfizer recorded a turnover of 25.7 billion dollars in the first quarter, an increase of 77% over one year, largely thanks to the income from the sale of its vaccine against Covid-19 .
The company has also maintained its forecast of selling $ 22 billion of its anti-Covid pill, Paxlovid, over the whole year.
On the other hand, it revised downwards its estimate of annual profit, mainly due to the change in accounting standards.
» SEE ALSO –
What is Paxlovid?
The anti-Covid pill that Pfizer is preparing to produce in France
